Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Slideshows|August 7, 2020
5 Fast Facts for Addressing Distress & Depression in Cancer
Despite advances in clinical care for patients with cancer, distress and depression continue to haunt patients. These fast facts will help you better understand and care for patients with cancer.
Advertisement
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
4
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
5